Humanigen Inc. (HGEN) Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme

April 9, 2021 7:00 AM EDT
Get Alerts HGEN Hot Sheet
Price: $16.73 -1.7%

Overall Analyst Rating:
    BUY (Down Down)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered® antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM). In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients. The results will be presented as a poster at the AACR Annual Meeting 2021, held virtually from April 10-15, 2021, and remain available until June 21, 2021.

The Phase 1 study primarily sought to determine the safety and recommended Phase 2 dose of ifabotuzumab in patients with GBM, the most frequent and lethal primary brain neoplasm, with 5-year survival rates of 10%. It is estimated there are more than 18,000 deaths from Brian cancer annually in the United States.1 Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors including breast, colon, lung, prostate, melanoma, and GBM. The study showed that, at both doses, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients. There were no dose-limiting toxicities observed and all adverse events were readily manageable. Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.

“GBM represents an extremely aggressive form of cancer that has historically eluded effective treatment, and we remain committed to investigating ifabotuzumab as a potential new approach to treat this devastating disease as well as other solid tumors,” said Prof. Andrew Scott, Head, Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Professor, School of Cancer Medicine, La Trobe University, member of the Australian Brain Cancer Mission Strategic Advisory Group, and Principal Investigator of the Phase 1 study. “The positive results of the Phase 1 study, which show ifabotuzumab to be well-tolerated and effective at targeting the EphA3 receptor, support further investigation into ifabotuzumab’s effect on other solid tumors in a Phase 2 study.”

The poster, titled “A phase 1 safety and bioimaging trial of ifabotuzumab (KB004) in patients with glioblastoma,” will be presented virtually at the AACR Annual Meeting during the Phase 1 Clinical Trials Session on Saturday, April 10, 2021. The study was led by Principal Investigator Andrew Scott from the Olivia Newton-John Cancer Research Institute in Australia. Funding was provided by Cure Brain Cancer Foundation, the Queensland Government, Austin Health, and Humanigen.

“We are pleased to announce the positive Phase 1 results of ifabotuzumab in patients with gliobastoma multiforme,” said Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. “There is a tremendous need to advance new therapies for solid tumors, and this trial shows that ifabotuzumab demonstrates great potential. Ifabotuzumab represents an important part of Humanigen’s immuno-oncology arsenal as we advance our pipeline to target a wide-range of cancers, and we are proud to present our findings at this year’s AACR Annual Meeting.”

Details for the upcoming event are below:

AACR Annual Meeting 2021

Virtual abstract presentation viewable starting on Friday, April 9, 2021
Register here:

E-poster presentation
Date: Saturday, April 10, 2021

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Related Entities